These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 33178392)
61. Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome. Panda R; Singh P; Kodamanchili S; Anand A Indian J Anaesth; 2021 Oct; 65(Suppl 4):S174-S176. PubMed ID: 34908570 [No Abstract] [Full Text] [Related]
62. Early identification of acute respiratory distress syndrome in times of the COVID-19 pandemic. Thille AW J Intensive Med; 2023 Jan; 3(1):1-3. PubMed ID: 36785581 [No Abstract] [Full Text] [Related]
63. Tension posterior pneumomediastinum in acute respiratory distress syndrome due to COVID-19. Lo Presti S; Mauro J; Mireles-Cabodevila E; Collier P Eur Heart J Case Rep; 2021 Mar; 5(3):ytab086. PubMed ID: 34192223 [No Abstract] [Full Text] [Related]
64. Worsening acute respiratory distress syndrome: Is it immune reconstitution inflammatory syndrome? Saroa R; Palta S; Aggarwal D; Gombar S; Saxena P Indian J Crit Care Med; 2013 Nov; 17(6):395-6. PubMed ID: 24501498 [No Abstract] [Full Text] [Related]
65. COVID-19 infection: mitohormetic concept of immune response. Gebicki J; Wieczorkowska M Cell Death Discov; 2020; 6():60. PubMed ID: 32690996 [No Abstract] [Full Text] [Related]
67. Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19. Zhu Y; Geng S; Li Q; Jiang H Front Bioeng Biotechnol; 2020; 8():557652. PubMed ID: 33224928 [TBL] [Abstract][Full Text] [Related]
68. Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. Rezakhani L; Kelishadrokhi AF; Soleimanizadeh A; Rahmati S Chem Phys Lipids; 2021 Jan; 234():105009. PubMed ID: 33189639 [TBL] [Abstract][Full Text] [Related]
70. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study. Feng Y; Huang J; Wu J; Xu Y; Chen B; Jiang L; Xiang H; Peng Z; Wang X Cell Prolif; 2020 Dec; 53(12):e12947. PubMed ID: 33205469 [TBL] [Abstract][Full Text] [Related]
71. Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? (Review). Çetin İ; Topçul M Biomed Rep; 2020 Dec; 13(6):62. PubMed ID: 33194191 [TBL] [Abstract][Full Text] [Related]
72. A safety consideration of mesenchymal stem cell therapy on COVID-19. Cao Y; Wu H; Zhai W; Wang Y; Li M; Li M; Yang L; Tian Y; Song Y; Li J; Wang Y; Ding Q; Zhang L; Cai M; Chang Z Stem Cell Res; 2020 Dec; 49():102066. PubMed ID: 33242791 [TBL] [Abstract][Full Text] [Related]
73. Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines. Tufan AC Curr Stem Cell Res Ther; 2021; 16(4):465-480. PubMed ID: 33238848 [TBL] [Abstract][Full Text] [Related]
74. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Avanzini MA; Mura M; Percivalle E; Bastaroli F; Croce S; Valsecchi C; Lenta E; Nykjaer G; Cassaniti I; Bagnarino J; Baldanti F; Zecca M; Comoli P; Gnecchi M Stem Cells Transl Med; 2021 Apr; 10(4):636-642. PubMed ID: 33188579 [TBL] [Abstract][Full Text] [Related]
75. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. Kumar V Int Immunopharmacol; 2020 Nov; 88():106980. PubMed ID: 33182073 [TBL] [Abstract][Full Text] [Related]
76. Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. Desterke C; Griscelli F; Imeri J; Marcoux P; Lemonnier T; Latsis T; Turhan AG; Bennaceur-Griscelli A Stem Cells Transl Med; 2021 Apr; 10(4):568-571. PubMed ID: 33237619 [TBL] [Abstract][Full Text] [Related]
77. Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19. Rodríguez C; Luque N; Blanco I; Sebastian L; Barberà JA; Peinado VI; Tura-Ceide O Am J Respir Cell Mol Biol; 2021 Apr; 64(4):407-415. PubMed ID: 33180562 [TBL] [Abstract][Full Text] [Related]
78. Diesel Particulate Matter 2.5 Induces Epithelial-to-Mesenchymal Transition and Upregulation of SARS-CoV-2 Receptor during Human Pluripotent Stem Cell-Derived Alveolar Organoid Development. Kim JH; Kim J; Kim WJ; Choi YH; Yang SR; Hong SH Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33202948 [TBL] [Abstract][Full Text] [Related]
79. Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Shetty R; Murugeswari P; Chakrabarty K; Jayadev C; Matalia H; Ghosh A; Das D Cytotherapy; 2021 Jun; 23(6):471-482. PubMed ID: 33257213 [TBL] [Abstract][Full Text] [Related]
80. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. Zheng H; Li H; Guo L; Liang Y; Li J; Wang X; Hu Y; Wang L; Liao Y; Yang F; Li Y; Fan S; Li D; Cui P; Wang Q; Shi H; Chen Y; Yang Z; Yang J; Shen D; Cun W; Zhou X; Dong X; Wang Y; Chen Y; Dai Q; Jin W; He Z; Li Q; Liu L PLoS Pathog; 2020 Nov; 16(11):e1008949. PubMed ID: 33180882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]